MD Pharmaceutical Supply Faces Renewed FDA Scrutiny Over Adulterated Ingredients

HANOVER, Pa. – MD Pharmaceutical Supply, LLC is facing new regulatory action from the U.S. Food and Drug Administration regarding its handling of active pharmaceutical ingredients (APIs), adding to a documented history of compliance failures. A new enforcement action, identified by the FDA with the date April 13, 2026, cites the Pennsylvania-based wholesaler for violations related to adulterated APIs and a failure to adhere to Current Good Manufacturing Practice (CGMP) standards. This latest action follows a previous, detailed warning letter issued to the company on November 22, 2022. In that letter, the FDA outlined significant deviations from federal regulations observed during an inspection of the company’s facility. The agency noted that MD Pharmaceutical Supply failed to establish effective procedures, maintain proper records, and implement robust controls for its operations as a wholesale distributor of APIs. Regulatory actions like these are often viewed as simple compliance issues, but they represent a significant financial and operational risk. For a small or mid-sized company in the pharmaceutical supply chain, an FDA warning letter can disrupt sales, freeze new product approvals, and trigger costly remediation efforts that strain capital and management attention. One of the specific failures detailed in the 2022 warning was the company’s handling of a Certificate of Analysis (COA) for a lot of aminocaproic acid API. FDA investigators found that the company possessed a COA with an expiration date of April 19, 2024. However, when the FDA requested the original COA from the supplier, it showed a different expiration date of April 19, 2023. According to the FDA, MD Pharmaceutical Supply distributed the API lot with the longer, one-year-extended expiration date but failed to initiate an investigation to determine if the change was scientifically justified or accurate. APIs are the core components in drugs that produce the intended therapeutic effect, and their purity, stability, and proper handling are critical for patient safety. CGMP regulations are the bedrock of pharmaceutical quality control, ensuring that drugs are consistently produced and controlled according to quality standards. A failure to investigate a discrepancy in expiration dates represents a serious lapse in these controls, as it could lead to the distribution of degraded or ineffective ingredients. In our experience, these situations often stem from business processes that haven't kept pace with growth or regulatory complexity. The failure to investigate a simple discrepancy in expiration dates points to a breakdown in quality management systems. This is precisely the kind of systemic weakness that our business process reengineering services are designed to identify and correct. We help clients build robust, auditable workflows that ensure compliance is a routine function, not a recurring crisis. For companies facing similar challenges, the first step is a thorough process review, and C&S Finance Group LLC at csfinancegroup.com can guide that engagement. MD Pharmaceutical Supply, LLC, led by Principal Richard Romeo, operates in the wholesale trade sector for drugs and druggists’ sundries, according to business data. As a merchant wholesaler, the company serves as a critical link in the nation's pharmaceutical supply chain. The consequences of failing to address the FDA’s citations can be severe. The 2022 letter warned that the agency could withhold the issuance of Export Certificates, effectively blocking the company from international markets. Furthermore, the FDA stated it could withhold approval of new drug applications or supplements that list MD Pharmaceutical Supply as a manufacturer or supplier until all deviations are fully corrected and compliance with CGMP is confirmed. The agency also reserved the right to conduct re-inspections to verify that corrective actions have been successfully implemented. The emergence of a new action related to adulterated APIs suggests that regulatory concerns persist. While the specific details of the action identified with the 2026 date have not been fully released, the citation for adulterated APIs points to continued problems with product quality and safety controls. Ultimately, proactive investment in operational integrity is far less costly than reacting to a public enforcement action that damages both reputation and the bottom line. These regulatory events underscore the FDA's ongoing focus on the integrity of the entire drug supply chain, from raw material suppliers to distributors and final manufacturers. Moving forward, MD Pharmaceutical Supply will be expected to provide a comprehensive response and remediation plan to the FDA to address the latest citations. The industry will be watching to see how the company resolves these compliance issues and whether the agency will pursue further enforcement measures, such as the previously mentioned holds on new applications or export certificates.